Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 22 2023 - 8:55AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 16, 2023
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Novo
Nordisk A/S – Share repurchase programme
Bagsværd,
Denmark, 16 February 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with
Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation
(EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme
of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023.
Under the programme initiated 1 February 2023, Novo Nordisk
will repurchase B shares for an amount up to DKK 5.6 billion in the period from 1 February 2023 to 2 May 2023.
Since the announcement of the programme, the following transactions
have been made:
| |
Number
of
B shares | | |
Average
purchase price | | |
Transaction
value, DKK | |
Accumulated, last announcement | |
| 387,564 | | |
| | | |
| 363,008,828 | |
7 February 2023 | |
| 95,000 | | |
| 965.23 | | |
| 91,696,711 | |
8 February 2023 | |
| 95,000 | | |
| 969.92 | | |
| 92,142,279 | |
9 February 2023 | |
| 95,000 | | |
| 967.08 | | |
| 91,872,915 | |
10 February 2023 | |
| 95,000 | | |
| 957.78 | | |
| 90,989,318 | |
13 February 2023 | |
| 91,000 | | |
| 983.14 | | |
| 89,466,090 | |
14 February 2023 | |
| 90,508 | | |
| 994.38 | | |
| 89,999,068 | |
15 February 2023 | |
| 95,000 | | |
| 981.80 | | |
| 93,271,444 | |
Accumulated under the programme | |
| 1,044,072 | | |
| | | |
| 1,002,446,653 | |
The details for each
transaction made under the share repurchase programme are published on novonordisk.com.
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 13/ 2023 |
Transactions related to Novo Nordisk’s incentive
programmes have resulted in a net transfer from Novo Nordisk of 15,115 B shares in the period from 7 February 2023 to 15 February 2023.
The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions
stated above, Novo Nordisk owns a total of 28,190,398 B shares of DKK 0.20 as treasury shares, corresponding to 1.2% of the share
capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.
Novo Nordisk expects
to repurchase B shares for an amount up to DKK 28 billion during a 12- month period beginning 1 February 2023. As of 15 February
2023, Novo Nordisk has since 1 February 2023 repurchased a total of 1,044,072 B shares at an average share price of DKK 960.13 per B
share equal to a transaction value of DKK 1,002,446,653.
Novo Nordisk is a
leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and
other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80
countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs
are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Contact for further information
Media: |
|
Ambre Brown Morley
+45 3079 9289
abmo@novonordisk.com |
Natalia Salomao
Abrahao (US)
+1 848 304 1027
niaa@novonordisk.com |
|
|
|
|
Investors: |
|
Daniel Muusmann
Bohsen
+45 3075 2175
dabo@novonordisk.com |
Jacob Martin Wiborg
Rode
+45 3075 5956
jrde@novonordisk.com |
|
|
|
|
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 13/ 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: February 16, 2023 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024